OrthoPediatrics (NASDAQ:KIDS – Get Free Report) and Olympus (OTCMKTS:OCPNY – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, earnings and dividends.
Profitability
This table compares OrthoPediatrics and Olympus’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| OrthoPediatrics | -15.72% | -8.10% | -5.54% |
| Olympus | 13.80% | 24.30% | 9.30% |
Insider & Institutional Ownership
69.1% of OrthoPediatrics shares are held by institutional investors. Comparatively, 0.0% of Olympus shares are held by institutional investors. 32.5% of OrthoPediatrics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Valuation & Earnings
This table compares OrthoPediatrics and Olympus”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| OrthoPediatrics | $252.72 million | 2.53 | -$39.65 million | ($1.68) | -14.58 |
| Olympus | $7.74 billion | 2.99 | $1.03 billion | $0.82 | 21.95 |
Olympus has higher revenue and earnings than OrthoPediatrics. OrthoPediatrics is trading at a lower price-to-earnings ratio than Olympus, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
OrthoPediatrics has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500. Comparatively, Olympus has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent recommendations for OrthoPediatrics and Olympus, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| OrthoPediatrics | 1 | 1 | 5 | 0 | 2.57 |
| Olympus | 0 | 0 | 1 | 0 | 3.00 |
OrthoPediatrics presently has a consensus target price of $26.50, suggesting a potential upside of 8.16%. Given OrthoPediatrics’ higher possible upside, equities research analysts plainly believe OrthoPediatrics is more favorable than Olympus.
Summary
Olympus beats OrthoPediatrics on 9 of the 14 factors compared between the two stocks.
About OrthoPediatrics
OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediguard, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIMTM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIROTM Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, and Mitchell Ponseti. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.
About Olympus
Olympus Corp. engages in the manufacture and sale of precision machineries and instruments. It operates through the following segments: Medical, Scientific Solutions, Imaging, and Others. The Medical segment covers digestive, surgical, and ultrasonic endoscopy as well as endoscopic treatment tools. The Scientific Solutions segment manufactures and sells biological and industrial microscopes, industrial endoscopes, and non-destructive testing equipment. The Imaging segment deals with digital cameras and recording devices. The Others segment includes biomaterial manufacturing and sales business. The company was founded by Takeshi Yamashita on October 12, 1919 and is headquartered in Tokyo, Japan.
Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.
